Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (13287)	1/14/1998 12:05:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Andy, Bernie mentioned Prostate for Targretin (and he also said that Panretin trials with Prostate do not look strong enough to continue).

To: Andrew H who wrote (13287)	1/14/1998 9:17:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Andy, I haven't been able to come up with a Targretin trial for breast cancer. As you know, not all trials are listed by NCI or Centerwatch, and only a handfull of medical centers have info on the web. I suspect that Targretin works slowly and its most effective at higher doses (second generation compounds like LGD1268 or LGD1364 will probably be equaklly effective at lower doses), and the breats data came up relatively recently as physician decided to try something new on advanced patients who were not responding to other treatments. However, Bernie indicated that LGND was now "aggressively" persuing advanced breast cancer with Targretin. Probably a few more television spots like those for Head & Neck, or a few presentation before advovacy groups could really start a fire. So far the street is still mostly on the sidelines, but RB did indicate NDA filings this year for oral and topical Targretin (for CTCL), so the street should wake up soon (he also predicted "significant" off-label use.